The Angiotensin II Receptor Blocker Losartan Sensitizes Human Liver Cancer Cells to Lenvatinib-Mediated Cytostatic and Angiostatic Effects

The Angiotensin II Receptor Blocker Losartan Sensitizes Human Liver Cancer Cells to Lenvatinib-Mediated Cytostatic and Angiostatic Effects

Molecular targeted therapy with lenvatinib is commonly offered to advanced hepatocellular carcinoma (HCC) patients, although it is often interrupted by adverse effects which require a reduction in the initial dose. Thus, an alternative lenvatinib-based therapy to compensate for dose reduction is ant...

Full description

Bibliographic Details
Main Authors: Hirotetsu Takagi, Kosuke Kaji, Norihisa Nishimura, Koji Ishida, Hiroyuki Ogawa, Hiroaki Takaya, Hideto Kawaratani, Kei Moriya, Tadashi Namisaki, Takemi Akahane, Akira Mitoro, Hitoshi Yoshiji
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Cells
Subjects:
HCC
VEGF
angiotensin-II
angiogenesis
lenvatinib
Online Access:https://www.mdpi.com/2073-4409/10/3/575

Internet

https://www.mdpi.com/2073-4409/10/3/575

Similar Items